Gregg L. Semenza
Gregg Leonard Semenza
1 July 1956 (age Expression error: Unrecognized word "july".–Expression error: Unrecognized word "july".)Expression error: Unrecognized word "july".
|Education||Harvard University (BA)|
University of Pennsylvania (MD, PhD)
|Known for||Hypoxia-inducible factors|
|Awards||Albert Lasker Award for Basic Medical Research (2016)|
Nobel Prize in Physiology or Medicine (2019)
|Institutions||Johns Hopkins School of Medicine|
|Thesis||Molecular genetic analysis of the silent carrier of beta thalassemia (haplotype) (1984)|
|Doctoral advisors||Elias Schwartz|
Gregg Leonard Semenza (born 1 July 1956) is an American Nobel Laureate who is the professor of pediatrics, radiation oncology, biological chemistry, medicine, and oncology at the Johns Hopkins University School of Medicine. He serves as the director of the vascular program at the Institute for Cell Engineering. He is a 2016 recipient of the Albert Lasker Award for Basic Medical Research. He is known for his discovery of HIF-1, which allows cancer cells to adapt to oxygen-poor environments. He shared the 2019 Nobel Prize in Physiology or Medicine for "discoveries of how cells sense and adapt to oxygen availability" with William Kaelin Jr. and Peter J. Ratcliffe.
Semenza graduated from Sleepy Hollow High School in 1974. As an undergraduate at Harvard University, he studied medical genetics and mapped genes on chromosome 21. For his PhD at the University of Pennsylvania, he sequenced genes linked to the recessive genetic disorder, beta-thalassemia Semenza subsequently completed his pediatrics residency at Duke University Hospital before completing a postdoctoral fellowship at Johns Hopkins University. Semenza became the founding director of the Vascular Program at the Johns Hopkins Institute for Cell Engineering following his post-doctorate.
While a post-doctorate researcher at John Hopkins, Semenza evaluated gene expression in transgenic animals to determine how this affected the production of erythropoietin (EPO), known to be part of the means for the body to react to hypoxia, or low oxygen levels in the blood. Semenza identified the gene sequences that expressed hypoxia-inducible factors (HIF) proteins. Semenza's work showed that the HIF proteins consisted of two parts; HIF-1β, a stable base to most conditions, and HIF-1α that deteriorated when nominal oxygen levels were present. HIF-1α was further found essential to the EPO production process, as test subjects modified to be deficient in HIF-1α were found to have malformed blood vessels and decreased EPO levels. these HIF proteins were found across multiple test animals. Semenza further found that HIF-1α overproduction could lead to cancer in other subjects.
Semenza's research overlapped with that of William Kaelin and Peter J. Ratcliffe on determining the mechanism of oxygen detection in cells, and how EPO production is regulated by HIF and other factors. This has led to the development of drugs that help regulate these processes for patients with anaemia and renal failure.
|Scholia has a profile for Gregg L. Semenza (Q1545025).|
Further support for an oxygen-sensing mechanism was provided by the discovery of erythropoietin (EPO), a glycoprotein hormone that stimulates erythrocyte production [...] During the same time period in which Semenza was developing EPO-transgenic mice, Peter Ratcliffe, a physician and kidney specialist, was establishing a laboratory in Oxford University’s Nuffield Department of Medicine to study the regulation of EPO